Etripamil
Medication
From Wikipedia, the free encyclopedia
Etripamil, sold under the brand name Cardamyst, is a medication used for the treatment of paroxysmal supraventricular tachycardia.[1] It is a calcium channel blocker.[1] It is used as a nasal spray.[1]
 | |
| Clinical data | |
|---|---|
| Trade names | Cardamyst |
| Other names | MSP-2017 |
| AHFS/Drugs.com | cardamyst |
| License data | |
| Routes of administration | Intranasal |
| Drug class | Calcium channel blocker |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C27H36N2O4 |
| Molar mass | 452.595 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Etripamil was approved for medical use in the United States in December 2025.[2]
Medical uses
Etripamil is indicated for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia to sinus rhythm.[1][3][4]
Pharmacology
Mechanism of action
Etripamil is a voltage-dependent L-type calcium channel inhibitor.[3]
Society and culture
Legal status
Etripamil was approved for medical use in the United States in December 2025.[2]
Names
Etripamil is the international nonproprietary name.[5]
Etripamil is sold under the brand name Cardamyst.[1]
